<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: An <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>-based regimen as the adjuvant treatment for stage III <z:hpo ids='HP_0003003'>colon cancer</z:hpo> demonstrated a survival advantage over fluorouracil (FU) and leucovorin (LV) in the MOSAIC and NSABP C-07 trials </plain></SENT>
<SENT sid="1" pm="."><plain>For adjuvant treatment after the resection of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> from <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>), active chemotherapy regimens such as FOLFOX are recommended </plain></SENT>
<SENT sid="2" pm="."><plain>However, the safety data of FOLFOX are insufficient for its use after metastasectomy of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> in Japanese patients </plain></SENT>
<SENT sid="3" pm="."><plain>The aim of this study was to evaluate the safety of mFOLFOX6 for adjuvant treatment after the resection of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> from <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: Among 67 consecutive patients who received mFOLFOX6 as the adjuvant treatment after resection of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> from <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> between September 2002 and March 2009 in our institution, 51 patients who had not received preoperative chemotherapy were reviewed </plain></SENT>
<SENT sid="5" pm="."><plain>The mFOLFOX6 treatment comprised <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> 85 mg/m(2) and l-leucovorin 200 mg/m(2) given intravenously over a 2-h period on day 1, followed by a 5-FU bolus of 400 mg/m(2) and a 46-h infusion of 5-FU 2400 mg/m(2), every 2 weeks for up to 12 cycles </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: National <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Institute Common Terminology Criteria for Adverse Events version 3.0 (NCI-CTC) grade 3-4 toxicities per patient were: <z:hpo ids='HP_0009830'>peripheral neuropathy</z:hpo> 8%, allergic reaction 4%, <z:chebi fb="0" ids="29995">aspartate</z:chebi> transaminase (AST) 4%, febrile <z:hpo ids='HP_0001875'>neutropenia</z:hpo> 4%, <z:hpo ids='HP_0002018'>nausea</z:hpo> 2%, <z:hpo ids='HP_0002039'>anorexia</z:hpo> 2%, <z:mp ids='MP_0002899'>fatigue</z:mp> 2%, alanine transaminase (ALT) 2%, <z:chebi fb="0" ids="16990">bilirubin</z:chebi> 2%, neutrophils 49%, leukocytes 6%, and <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> 2%; 71% of the patients completed the scheduled 12 cycles </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSION: Adjuvant therapy with mFOLFOX6 after resection of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> from <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> is feasible for Japanese patients </plain></SENT>
</text></document>